Kiora Pharmaceuticals, Inc. ((KPRX)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Kiora Pharmaceuticals, Inc. is conducting a Phase I/II clinical study titled ‘A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)’. The primary goal is to evaluate the safety, tolerability, and efficacy of KIO-301, a promising treatment for retinitis pigmentosa and choroideremia, potentially offering new hope for patients with these degenerative eye conditions.
The intervention being tested is KIO-301, a drug administered via intravitreal injection. This treatment aims to address the underlying causes of vision loss associated with retinitis pigmentosa and choroideremia.
The study follows an interventional, open-label design with a single-group assignment. There is no masking involved, and the primary purpose is treatment, focusing on the effects of KIO-301 on the targeted conditions.
The study began on March 8, 2022, and is currently recruiting participants. The last update was submitted on September 2, 2025, indicating ongoing progress. These dates are crucial for tracking the study’s development and potential market entry.
The update on this study could positively influence Kiora Pharmaceuticals’ stock performance by enhancing investor confidence in the company’s innovative pipeline. As the study progresses, it may also impact the competitive landscape in the treatment of retinal diseases.
The study is ongoing, with further details available on the ClinicalTrials portal.